氏病的表型,诊断和治疗方法
1Cincinnati Children's Hospital Medical Center, Division of Human Genetics, Department of Pediatrics, University of Cincinnati, Cincinnati, OH, USA.
Lancet (London, England)
|December 20, 2008
概括
氏病的研究推动了分子医学的发展,确定了酶疗法对内脏表现的有效性. 创新旨在为神经病变种和其他遗传性疾病提供经济有效的治疗方法.
科学领域:
- 分子医学是分子医学.
- 遗传学 是一个遗传学.
- 生物化学 生物化学
背景情况:
- 氏病是理解分子医学应用的一个关键模型.
- 广泛的分析已经确定了多种疾病变异,并建立了基因型-表型相关性.
研究的目的:
- 审查高氏病研究的进展,重点关注分子医学.
- 突出酶疗法的有效性,并探索新的治疗策略.
主要方法:
- 分析了成千上万患有高氏病的个体的数据.
- 审查当前和新兴的治疗策略,包括酶疗法,基质枯竭和药理伴侣.
主要成果:
- 酶疗法有效地抑制或逆转内脏疾病的进展.
- 对种族差异,预后和结果的理解得到了改善.
- 新的治疗策略对神经病变体有希望.
结论:
- 分子医学显著改善了高氏病的诊断和治疗.
- 新型疗法,包括基质耗尽和护送策略,提供了更广泛的应用和成本效益的潜力.
- 这些进展有利于患有高氏病和其他 lysosomal 和遗传性疾病的患者.
更多相关视频
相关概念视频
Lysosomal Hydrolases
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
Inborn Errors of Metabolism
Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Pedigree Analysis
Overview
Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...


